Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer 1 min read People and Community Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer AETOSWire October 12, 2022 CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence...Read More